A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (OBERON) (OBERON)
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab
Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic
COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12
months. Participants should be receiving optimised treatment with maintenance inhaled therapy
(ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in
stable doses throughout at least 3 months prior to enrolment.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.